Published in Horm Cancer on November 25, 2014
Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma. Expert Opin Ther Targets (2015) 0.75
Mouse models of thyroid cancer: A 2015 update. Mol Cell Endocrinol (2015) 0.75
Selective Ablation of Tumor Suppressors in Parafollicular C Cells Elicits Medullary Thyroid Carcinoma. J Biol Chem (2017) 0.75
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
MAP kinase signalling pathways in cancer. Oncogene (2007) 8.52
Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 8.04
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res (2009) 3.56
Bcl-2 family proteins and cancer. Oncogene (2008) 3.42
Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab (2008) 2.89
Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene (2003) 2.54
Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery (2001) 2.50
Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid (2002) 2.18
The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab (2013) 2.17
Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer (2008) 2.10
ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol (2003) 2.07
Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid (2010) 2.05
RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res (1998) 2.00
Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene (2005) 1.99
Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest (2011) 1.97
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A (2013) 1.72
Critical role of STAT3 in leptin's metabolic actions. Cell Metab (2006) 1.70
Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab (1999) 1.65
Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. Mol Cancer Res (2014) 1.65
Anaplastic thyroid cancer. Endocrinol Metab Clin North Am (2008) 1.54
Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest (1992) 1.52
Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res (1994) 1.49
Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle and giant cell carcinoma of the thyroid. Cancer (1978) 1.45
Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis. Cancer Res (2007) 1.38
BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med (2013) 1.38
Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr Opin Cell Biol (2009) 1.37
PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer. Oncogene (2008) 1.31
Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol (2004) 1.26
Sites of metastases of anaplastic thyroid carcinoma: autopsy findings in 45 cases from a single institution. Thyroid (2013) 1.23
Functionally impaired TR mutants are present in thyroid papillary cancer. J Clin Endocrinol Metab (2002) 1.23
Thyroid carcinoma after Chernobyl latent period, morphology and aggressiveness. Br J Cancer (2004) 1.20
Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. Oncotarget (2011) 1.19
p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci U S A (2014) 1.14
Anaplastic thyroid carcinoma: an overview. Curr Oncol Rep (2007) 1.12
Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females. Oncogene (2010) 1.11
Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review. BMC Surg (2013) 1.10
Anaplastic thyroid carcinoma: palliation or treatment? Curr Opin Otolaryngol Head Neck Surg (2011) 1.08
Biological challenges of BRAF inhibitor therapy. Mol Oncol (2011) 1.08
Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer. Int J Endocrinol (2014) 1.07
SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer. Clin Cancer Res (2012) 0.99
Mechanism and consequences of RAF kinase activation by small-molecule inhibitors. Br J Cancer (2014) 0.97
Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer. Carcinogenesis (2010) 0.96
Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways. Cell Death Dis (2014) 0.96
Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation. Neoplasia (2014) 0.96
Diet-induced obesity increases tumor growth and promotes anaplastic change in thyroid cancer in a mouse model. Endocrinology (2013) 0.92
18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging (2010) 0.91
Thyroid-stimulating hormone, thyroglobulin, and thyroid hormones and risk of differentiated thyroid carcinoma: the EPIC study. J Natl Cancer Inst (2014) 0.90
Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Am J Pathol (2000) 0.90
The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations. Thyroid (2013) 0.89
The role of epithelial mesenchymal transition markers in thyroid carcinoma progression. Endocr Pathol (2013) 0.89
Basal STAT3 activities are negatively correlated with tumor size in papillary thyroid carcinomas. J Endocrinol Invest (2011) 0.87
Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. J Clin Endocrinol Metab (2012) 0.85
Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma. Transl Res (2014) 0.85
Update on thyroid cancer treatment. Future Oncol (2012) 0.85
Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1: a paradigm shift that impacts current therapeutic strategies. J Cell Sci (2012) 0.85
Expression of the cell death-inducing gene bax in carcinomas developed from the follicular cells of the thyroid gland. J Clin Endocrinol Metab (1996) 0.83
Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor. Future Oncol (2012) 0.82
Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression. Endocr Relat Cancer (2014) 0.82
Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71. Int J Endocrinol (2014) 0.78
Obesity and thyroid cancer: is leptin the (only) link? Endocrinology (2013) 0.78
DNA aneuploidy in anaplastic carcinoma of the thyroid gland. Am J Clin Pathol (1988) 0.76
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res (2005) 4.74
The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev (2006) 2.76
Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol (2002) 2.15
PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway. Gastroenterology (2002) 2.03
The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. Immunity (2002) 1.70
Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res (2009) 1.65
Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA (2005) 1.59
Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene (2005) 1.48
Establishment and characterization of cell lines from a novel mouse model of poorly differentiated thyroid carcinoma: powerful tools for basic and preclinical research. Thyroid (2011) 1.47
PTEN in neural precursor cells: regulation of migration, apoptosis, and proliferation. Mol Cell Neurosci (2002) 1.43
Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis. Cancer Res (2007) 1.38
Class reunion: PTEN joins the nuclear crew. Oncogene (2005) 1.31
Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development. Cancer Res (2009) 1.26
Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation. Cancer Res (2005) 1.24
Role of Dok-1 and Dok-2 in leukemia suppression. J Exp Med (2004) 1.23
Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-OH-initiated proliferative signals in the thyroid follicular epithelium. Cancer Res (2008) 1.20
A novel recurrent chromosomal inversion implicates the homeobox gene Dlx5 in T-cell lymphomas from Lck-Akt2 transgenic mice. Cancer Res (2008) 1.19
Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. Oncotarget (2011) 1.19
Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/- mice. Cancer Res (2006) 1.07
Transcriptional regulation of the human tumor suppressor p14(ARF) by E2F1, E2F2, E2F3, and Sp1-like factors. Biochem Biophys Res Commun (2002) 1.00
GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt. Clin Cancer Res (2010) 0.96
Inhibition of AMPK and Krebs cycle gene expression drives metabolic remodeling of Pten-deficient preneoplastic thyroid cells. Cancer Res (2013) 0.95
Thyroid-stimulating hormone initiated proliferative signals converge in vivo on the mTOR kinase without activating AKT. Cancer Res (2007) 0.94
Gene expression analysis reveals a signature of estrogen receptor activation upon loss of Pten in a mouse model of endometrial cancer. J Cell Physiol (2006) 0.89
The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations. Thyroid (2013) 0.89
In vivo adenovirus-mediated gene transduction into mouse endometrial glands: a novel tool to model endometrial cancer in the mouse. Gynecol Oncol (2004) 0.84
Three-dimensional nuclear telomere architecture changes during endometrial carcinoma development. Genes Chromosomes Cancer (2013) 0.78
Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer. Endocrinology (2013) 0.78
New routes to old places: PIK3R1 and PIK3R2 join PIK3CA and PTEN as endometrial cancer genes. Cancer Discov (2011) 0.77
Mouse models of follicular and papillary thyroid cancer progression. Front Endocrinol (Lausanne) (2012) 0.76